BDNF and amyotrophic lateral sclerosis: Despite promising outcomes from select research conducted in preclinical animal models, a large-scale clinical trial involving oral BDNF supplementation in patients with amyotrophic lateral sclerosis (ALS) did not significantly increase patient survival at dosages of 50–100 mg/day [184].